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ABSTRACT 
Background: Preemptive analgesia used for postsurgical pain management 
has been shown to reduce the requirements of postoperative analgesics. 
Objective: The aim of this study was to compare the preemptive analgesic 
effects of diflunisal, naproxen sodium, meloxicam, acetaminophen, and rofecox- 
ib (no longer available in some markets) in patients undergoing ambulatory 
dental surgery and the need for postoperative pain management in these 
patients. 
Methods: This prospective, randomized, single-blind study was conducted 
at the Departments of Anesthesiology and Reanimation and Oral and Maxil- 
lofacial Surgery, Baskent University, Adana Teaching and Medical Research 
Center, Adana, Turkey. Turkish outpatients aged ___16 years with American 
Society of Anesthesiologists physical status 1 (ie, healthy) and scheduled to 
undergo surgical extraction of an impacted third molar were enrolled. Patients 
were randomly assigned to receive diflunisal 500 mg, naproxen sodium 550 mg, 
meloxicam 7.5 mg, acetaminophen 500 mg, or rofecoxib 12.5 mg. All medications 
were administered orally 1 hour before surgery as preemptive analgesia nd 
after surgery if needed, up to the maximum recommended dose. Surgery was 
performed with the patient under local anesthesia (articaine hydrochloride). 
Pain intensity was assessed using a 100-mm visual analog scale (VAS) (0 = none 
to 100 = worst possible pain) at 2, 4, 6, and 12 hours after ambulatory surgery. 
The use of additional analgesics was recorded for 24 hours using patient diaries. 
Postoperative adverse ev nts were recorded using the diaries. 
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Results: One hundred fifty patients (108 women, 42 men; mean [SE] age, 26.8 
[0.6] years; 30 patients per group) had data available for analysis. Demographic 
data were similar between the 5 groups. No significant differences in mean VAS 
scores were found between the 5 groups at any time point. All mean VAS scores 
indicated minor pain. The rate of additional postoperative analgesics required 
was significantly lower in the diflunisal group compared with groups receiving 
naproxen sodium, meloxicam, acetaminophen, and rofecoxib (3 [10%] patients 
vs 11 [37%], 15 [50%], 15 [50%], and 14 [47%] patients, respectively; all, P < 
0.05). Bleeding at the surgical site was reported in 2 patients each in the diflu- 
nisal, naproxen sodium, meloxicam, and acetaminophen groups, and in 1 pa- 
tient in the rofecoxib group; the between-group differences were not signifi- 
cant. No significant differences in the prevalences of other adverse ffects (eg, 
nausea, vomiting, allergy, gastrointestinal symptoms) were found between the 
5 treatment groups. 
Conclusions: In the present study in patients undergoing third molar extrac- 
tion, adequate preemptive analgesia, based on VAS scores, was found with all of 
the nonopioid analgesic agents used. Fewer patients required rescue medica- 
tion with diflunisal. All 5 study drugs were similarly well tolerated. (Curr Ther 
Res Clin Exp. 2005;66:541-551) Copyright © 2005 Excerpta Medica, Inc. 
Key words: preemptive analgesia, ambulatory surgery, NSAIDs. 
INTRODUCTION 
An increasing number of studies have focused on the use of preemptive anal- 
gesia for postoperative pain relief. 1 It has been found that pain scores imme- 
diately after surgery are significantly improved with the use of preemptive 
analgesia. 2 NSAIDs and other nonopioid analgesics are commonly used for 
postoperative pain relief in ambulatory surgery. 3,4 Studies have found that 
the analgesic effect of rofecoxib administered postoperatively was signifi- 
cantly greater than that achieved with celecoxib, acetaminophen plus 
codeine, ibuprofen, or diclofenac sodium. 5-8 However, rofecoxib was with- 
drawn from some markets due to concerns regarding cardiovascular dverse 
effects. Also, these studies are controversial because the maximum recom- 
mended aily dose of rofecoxib was prescribed, whereas in other studies, 7,8 
it was not. Among NSAIDs, diflunisal, naproxen sodium, ibuprofen, acetamin- 
ophen, and rofecoxib have been used for preemptive analgesia, and have 
been found to be effective in alleviating various degrees of postoperative 
pain.4, 9-12 
Surgical extraction of impacted third molars constitutes an accepted 
model to clinically assess the need for analgesic medications. 5,7The aim of 
the present study was to compare the preemptive analgesic effects of medi- 
cations (diflunisal, naproxen sodium, meloxicam, acetaminophen, and rofe- 
coxib) currently used in Turkey for postoperative pain management in ambu- 
latory surgery. 
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PATIENTS AND METHODS 
This prospective, randomized, single-blind study was conducted at the 
Departments of Anesthesiology and Reanimation and Oral and Maxillofacial 
Surgery, Baskent University, Adana Teaching and Medical Research Center, 
Adana, Turkey, between February and July 2004. Approval of the protocol was 
obtained from the local ethics committee. Consecutive Turkish outpatients 
aged ___16 years with American Society of Anesthesiologists physical status 1 (ie, 
healthy) and scheduled to undergo surgical extraction of an impacted third 
molar were enrolled. Written informed consent was obtained from patients or 
their parents/legal guardians for those under 18 years of age. Patients were 
excluded if they had allergy to any analgesic, asthma, peptic ulcer disease, a 
bleeding disorder, intolerance to NSAIDs, and/or a history of renal and/or 
hepatic insufficiency. Patients who were pregnant also were excluded. 
Study Medications 
On the morning of surgery, eligible patients were randomly assigned, in a 1:1 
ratio using a computer-generated list of random numbers, to receive oral treat- 
ment with diflunisal, naproxen sodium, meloxicam, acetaminophen, or rofe- 
coxib. The dose selected for each drug was that most commonly prescribed 
based on information in the literature (MEDLINE search; key terms: nonopioid 
analgesics, efficacy, and tolerability; years: 1980-2005), 13-16 and were as follows: 
diflunisal, 500 mg; naproxen sodium, 550 mg; meloxicam, 7.5 mg; acetamino- 
phen, 500 mg; and rofecoxib, 12.5 mg. The first dose was administered 1 hour 
before surgery. The second dose was administered not before 2 hours after sur- 
gery as rescue medication on patient request. The third dose was also adminis- 
tered on patient request and was not allowed before the stated dosing interval 
for each drug (12 hours after the second dose for diflunisal, naproxen sodium, 
meloxicam, and rofecoxib; 6 hours for acetaminophen). The use of a second 
dose before the recommended dosing interval was considered additional anal- 
gesic use. The maximum total amount allowed per 24-hour period was deter- 
mined based on the recommended dosing interval of each drug, as follows: 
diflunisal, 1500 mg17; naproxen sodium, 1650 mg18; meloxicam, 22.5 mg19; aceta- 
minophen, 4000 mg15; and rofecoxib, 50 mg. 3'13 
Blinding of the study investigators, urgeons, and other health care staff was 
maintained using identical packaging of the study drugs. Patients were un- 
blinded to treatment and they had full knowledge of the analgesic agent used; 
they received prescriptions for the medications before surgery and could use 
them if needed in the postoperative period. 
The same surgeon performed all of the surgeries in a standardized manner, 
with each patient receiving local anesthesia (inferior alveolar, lingual, and buc- 
cal nerve blocks maintained using 2 mL of articaine hydrochloride 40 mg/mL 
with epinephrine hydrochloride 0.006 mg/mL). At 1 hour after surgery, patients 
were discharged with study medication and a diary and advised to rest at home 
for 12 hours. 
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Assessments 
Pain intensity was assessed using a written 100-mm visual analog scale (VAS) 
(0 = none to 100 = worst possible pain) at 2, 4, 6, and 12 hours after surgery. 
Patients used a diary to record the need for additional analgesic for 24 hours. 
Postoperative adverse ffects, including nausea, vomiting, allergy, and bleed- 
ing from the surgical site, also were recorded in the diary over 24 hours. 
Statistical Analysis 
Statistical analyses were performed using SPSS version 11.0 (SPSS Inc., 
Chicago, Illinois). A sample size of 30 for each group was determined for a 
power of 80% at an ~ level of 0.05. The ~2 test was used to analyze group differ- 
ences in the distribution of categoric data; 1-way analysis of variance for 
repeated measurements was used to compare the 5 groups; and the Kruskal- 
Wallis and Mann-Whitney U tests were used to compare nonparametr ic  data 
between the groups. Data are presented as mean (SE). P < 0.05 was considered 
statistically significant. 
RESULTS 
Study Population 
Two hundred eight patients were enrolled in the study; 153 completed it. 
Forty patients were excluded because of a lack of consent; 15, because of exclu- 
sion criteria. Three of the 153 patients who completed the study did not return 
for follow-up and were excluded from the analysis. Thus, 150 patients returned 
for follow-up and returned the questionnaire and patient diary and were in- 
cluded in the analysis (108 women, 42 men; mean [SE] age, 26.8 [0.6] years; 30 pa- 
tients per group) (Table I). The mean operative time was 12.34 (0.77) minutes. No 
significant between-group differences in the baseline criteria were found. 
Efficacy 
No statistically significant between-group differences were found in mean VAS 
scores at 2, 4, 6, or 12 hours after surgery (Table If). 
The rate of additional postoperat ive analgesics required was significantly 
lower in the diflunisal group compared with groups receiving naproxen sodium, 
meloxicam, acetaminophen, and rofecoxib (3 [10%] patients vs 11 [37%], 15 
[50%], 15 [50%], and 14 [47%] patients, respectively; all, P< 0.05) (Figure). 
Tolerability 
Bleeding at the surgical site was reported in 2 patients each in the diflunisal, 
naproxen sodium, meloxicam, and acetaminophen groups, and in 1 patient in 
the rofecoxib group; the between-group differences were not significant. No sig- 
nificant differences in the prevalences of other adverse effects (eg, nausea, 
vomiting, allergy, gastrointestinal [GI] symptoms) were found between groups. 
The most common drug-related adverse events were nausea and vomiting 
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Table II. Postoperative visual analog scale scores.* Values are mean (SE). 
Study Group 2 Hours 4 Hours 6 Hours 12 Hours 
Diflunisal 
(n = 30) 22.67 (4.1) 22.93 (4.0) 22.33 (3.6) 19.93 (3.3) 
Naproxen sodium 
(n = 30) 16.93 (4.4) 26.10 (4.8) 25.36 (4.6) 21.56 (4.5) 
Meloxicam 
(n = 30) 16.60 (4.4) 19.23 (3.8) 18.76 (4.3) 17.96 (4.6) 
Acetaminophen 
(n = 30) 16.56 (3.8) 27.23 (4.4) 27.1 6 (4.8) 20.90 (5.2) 
Rofecoxib 
(n = 30) 13.10 (3.5) 24.10 (4.9) 24.10 (4.9) 18.20 (3.4) 
P 0.591 0.743 0.737 0.968 
*Scale: 0 = no pain to 100 = worst possible pain. 
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Figure. Postoperative additional analgesic requirements by study group. *P < 0.05 
diflunisal versus all other groups. 
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(22.7% and 4% of patients, respectively). Severe bleeding, persistent nausea nd 
vomiting, or NSAID-related acute erosive gastritis was not reported. 
DISCUSSION 
Effective analgesia fter ambulatory surgery is important in maintaining patient 
comfort. 2° Preemptive use of oral NSAIDs has been shown to provide effective 
postoperative analgesia fter ambulatory surgery. 3,21,22 Surgical extraction of an 
impacted third molar is an accepted model for assessing analgesic efficacy. 5,7 
Thus, the present study was designed to compare the preemptive analgesic 
effects of nonopioids (diflunisal, naproxen sodium, meloxicam, acetaminophen, 
rofecoxib) commonly used in ambulatory dental surgery. 
Effectiveness 
Studies have found that preemptive administration of diflunisal 1000 mg, 
naproxen sodium 550 to 1000 mg, and rofecoxib 25 to 50 mg provided sufficient 
analgesia fter ambulatory dental surgery. 3,6,1°,11,21,23-28 In the present study, 
because all of the mean VAS scores were <30 mm at 2, 4, 6, and 12 hours post- 
operatively in each group, it could be stated that postoperative analgesia was 
adequate with all 5 agents. 
Because a significantly lower proportion of patients who preemptively re- 
ceived diflunisal required additional postoperative analgesia compared with 
patients in the other groups, we consider that the preemptive analgesic effect 
of diflunisal was greater than that of the other analgesics studied. 
Dosing Considerations 
According to the study protocol, the first dose of the analgesic agent, which 
would otherwise be prescribed postoperatively, was administered 1 hour before 
surgery. Doses of analgesics given did not exceed recommended maximum 
daily doses. 13-16 Although the doses selected for the analgesics were derived 
from the literature, 13-16 with the assumption that these doses represented the 
optimal analgesic doses of these drugs, we recognize that the doses of the study 
drugs might not have been equipotent. 
In the authors' opinion, whether the total daily dose of prescribed analgesic 
should be administered once preemptively or the first divided dose of the daily 
regimen should be received preemptively is debatable. Postoperative administra- 
tion of a prescribed aily dose of a selected analgesic on an outpatient basis as 
an additional analgesic at the patient's request, with the first dose having already 
been given preemptively, could be a more accurate and feasible approach. The 
analgesic regimen could then be continued postoperatively for 24 to 48 hours. 
Inadequate pain relief after the preemptive administration f rofecoxib 50 mg 
(maximum daily dose) might result in maintenance of the same analgesic agent 
postoperatively; hence, there is a risk for exceeding the maximum recom- 
mended aily dose or the need to prescribe another analgesic. Administration 
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of rofecoxib 50 mg preemptively is disadvantageous because of the high inci- 
dence of severe adverse effects associated with the use of maximum doses 
when postoperative analgesic use is required. However, White 3 recommended 
a dose of 25 to 50 mg of rofecoxib for preemptive analgesia, and administration 
of rofecoxib 12.5 mg BID is a common practice in acute pain management after 
oral surgery. 29 The review of the literature did not find other studies using pre- 
emptive administration of rofecoxib 12.5 mg; hence, this dose of rofecoxib as 
used in our study could be considered low. However, recent studies indicate 
that doses of rofecoxib >25 mg are associated with an increased risk for 
sudden cardiac death and acute myocardial infarction. 3°,31 Considering this, 
we do not suggest a preemptive dose of rofecoxib >12.5 mg. If patients in the 
present study experienced pain after surgery, they received the preemptively 
administered rugs again postoperatively based on the recommended daily 
doses. 
Tolerability 
NSAIDs have been associated with GI bleeding and dyspepsia. 9,32-35 The inci- 
dence of GI adverse ffects, including dyspepsia nd bleeding, with the admin- 
istration of cyclooxygenase-2 (COX-2) inhibitors has been reported as being 
lower compared with that found with nonselective NSAIDs. This finding could 
be considered an advantage of COX-2 inhibitors. 35-38 However, Laporte et a133 
failed to confirm that greater selectivity for COX-2 inhibitors was associated 
with less risk for upper GI bleeding compared with other NSAIDs. Instead, they 
found that the risk for GI complications was dependent on the particular drug 
and its dose. As mentioned previously, Layton et a132 did not find any significant 
differences in the prevalences of adverse ffects in patients receiving rofecoxib 
or meloxicam. Use of rofecoxib for pain management after third molar extrac- 
tion has not been associated with prolonged bleeding from the surgical site. 38 
The present study did not find any significant between-group differences in the 
prevalences of bleeding or other complications. It should be noted that some 
COX-2 inhibitors have been removed from the US market. 
Study Limitations 
Limitations of this study include a relatively small sample size per group and 
the lack of blinding of the patients. In addition, the results cannot be extrapo- 
lated to patients undergoing third molar extraction who do not meet the inclu- 
sion criteria of this study. Last, as mentioned, the doses used might not have 
been equipotent. Future studies should be performed on equipotent doses of 
analgesics because their comparisons are more accurate. 
CONCLUSIONS 
In the present study in patients undergoing third molar extraction, adequate 
preemptive analgesia, based on VAS scores, was found with all of the nonopioid 
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analgesic agents used. Fewer patients required rescue medication with diflu- 
nisal. All 5 study drugs were similarly well tolerated. 
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